Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in Relapsed/Refractory B-precursor ALL
NCT01466179Phase 2Completed
- Sponsor
- Amgen
- Start
- Dec 2011
- Primary completion
- Oct 2013
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Amgen. Started Dec 2011; status: completed.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT01466179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01466179.